ABL Bio’s givastomig wins FDA Fast Track designation

매일경제·Jun 18

This story is reported by 매일경제. Read what other outlets are saying below, then open the original report for full details.

Full coverage

1

ABL Bio wins FDA fast track for gastric cancer drug Jivastomig; phase 3 set - CHOSUNBIZ

Chosunbiz·Jun 17

2

ABL Bio’s US partner wins FDA’s orphan drug designation for bile duct cancer drug Tovecimig

koreabiomed.com·Apr 8

3

ABL Bio's Gastric Cancer Drug 'Givastomig' Clears Path for FDA Accelerated Approval... Phase 3 Trial to Begin This Year

finance.biggo.com·Mar 16

4

ABL Bio, NovaBridge see FDA accelerated approval path for gastric cancer drug Givastomig

koreabiomed.com·Mar 17

5

ABL Bio presents Grabody-T clinical progress at global bispecific antibody summit

koreabiomed.com·Jun 12

6

FDA Fast Track boosts NovaBridge (NBP) gastric cancer antibody givastomig

Stock Titan·Jun 16

7

ABL Bio to spotlight bispecific ADC ABL209 at World ADC Korea

koreabiomed.com·Jun 8

8

Coupang faces June 10 ruling over data leak affecting 33 mn users

매일경제·Jun 10